We are pleased to announce that Gyrolab® Bioaffy™ 1000 HC CD is now available for order as a standalone product:
P0020245 Gyrolab Bioaffy 1000 HC CD
Gyrolab Bioaffy 1000 HC CD uses a 1000nL sample volume and is packed with porous streptavidin coated beads that have a higher binding capacity for biotinylated capture reagents compared to the solid beads in Gyrolab Bioaffy 1000 CD. This CD has demonstrated improved performance in assays where reagents demonstrate lower binding affinity to the analytes.
To support assay development using Gyrolab Bioaffy 1000 HC CD, four new Gyrolab methods are available for download from our Gyrolab User Zone.
Gyrolab Viewer software
To aid in the selection of the optimal CD for your assay, Gyrolab Viewer software is a unique tool to assess the quality of the binding event for the best assay performance, provides CD selection guidance and will save valuable assay development time and generate better results. In the example below, the column profiles of standard and sample are compared for Gyrolab Bioaffy 1000 CD and Gyrolab Bioaffy 1000 HC CD. Based on the peak shape of the column profile, Gyrolab Bioaffy 1000 HC is a better selection for the reagents used in this particular assay.
Gyrolab Assay Protocols
Gyrolab assay protocols are available to provide carefully tested Gyrolab assay methods for commonly used immunoassays including biosimilar PK and biomarker assays. These methods specify the assay design, CD type, antibody reagents, Rexxip buffer, dilutions, and needle wash buffers to accelerate assay development. Check our Gyrolab Assay Protocols page often, as we are frequently posting more assays.
SARS-CoV-2 Total Antibody Assay
In response to the COVID-19 pandemic, we have developed a Gyrolab immunoassay for SARS-CoV-2 antibodies in human serum samples. A three-step bridging assay uses biotinylated SARS-CoV-2 Spike RBD-His recombinant protein as the capture molecule and SARS-CoV-2 Spike RBD-Fc recombinant protein labeled with Alexa Fluor® 647 as the detection molecule. The assay detects total antibodies against the receptor binding domain of the spike protein of SARS-CoV-2 in human serum samples.
Recently regulatory agencies have lowered the sensitivity requirement for ADA detection, from 250-500 ng/mL to 100 ng/mL. To reach such sensitivity levels without affecting the assay drug tolerance, sample pre-treatment steps may be necessary. Gyrolab ADA immunoassays using the mixing CD for automated acid dissociation steps streamlines ADA assay workflows and improves sensitivity and drug tolerance of ADA assays while reducing variability and saving time.
We have developed a Gyrolab protocol for a homogenous bridging Gyrolab ADA assay to determine levels of anti-Actemra antibodies in human serum samples.
To learn more about the range of Gyrolab Bioaffy CDs and automated immunoassay applications, please visit www.gyrosproteintechnologies.com or contact your local Regional Sales Manager.